Regression of Cardiac Lymphoma With Chemotherapy

Juan Fernández-Martínez1, Martín Descalzo-Buey1, Irene Menduiña-Gallego1

  • 1Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

JACC. Case Reports
|January 24, 2024
PubMed

Insights

Chest pain and myocardial changes in a patient were linked to lymphoma. Positron emission tomography and computed tomography revealed hypermetabolism and adenopathies. Chemotherapy led to regression of hypertrophy and edema.

Area of Science:

  • Cardiology
  • Oncology
  • Radiology

Background:

  • Chest pain and electrocardiographic changes are common presenting symptoms requiring thorough investigation.
  • Cardiac magnetic resonance (CMR) and combined positron emission tomography-computed tomography (PET-CT) are advanced imaging modalities for cardiac and oncologic evaluation.

Observation:

  • A patient presented with chest pain and electrocardiographic abnormalities.
  • Cardiac magnetic resonance imaging revealed focal myocardial hypertrophy attributed to edema.
  • Combined PET-CT demonstrated myocardial hypermetabolism and multiple adenopathies.

Findings:

  • Biopsy confirmed the adenopathies were consistent with lymphoma.
  • The patient's myocardial hypertrophy and edema showed significant regression following chemotherapy.

Implications:

  • This case highlights the utility of integrated imaging techniques (CMR and PET-CT) in diagnosing complex cardiac conditions.
  • It underscores the importance of considering systemic diseases like lymphoma in the differential diagnosis of myocardial abnormalities.
  • Successful chemotherapy treatment indicates a potential therapeutic target for lymphoma-induced cardiac manifestations.